Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,303 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy.
Ronner E, Boersma E, Laarman GJ, Somsen GA, Harrington RA, Deckers JW, Topol EJ, Califf RM, Simoons ML. Ronner E, et al. Among authors: topol ej. J Am Coll Cardiol. 2002 Jun 19;39(12):1924-9. doi: 10.1016/s0735-1097(02)01897-1. J Am Coll Cardiol. 2002. PMID: 12084589 Free article. Clinical Trial.
Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy).
Breeman A, Mercado N, Lenzen M, van den Brand MM, Harrington RA, Califf RM, Topol EJ, Simoons ML, Boersma E; PURSUIT Investigators. Breeman A, et al. Among authors: topol ej. Cardiology. 2002;98(4):195-201. doi: 10.1159/000067321. Cardiology. 2002. PMID: 12566649 Clinical Trial.
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.
Akkerhuis KM, Deckers JW, Boersma E, Harrington RA, Stepinska J, Mahaffey KW, Wilcox RG, Lincoff AM, Keltai M, Topol EJ, Califf RM, Simoons ML. Akkerhuis KM, et al. Among authors: topol ej. Eur Heart J. 2000 Mar;21(5):371-81. doi: 10.1053/euhj.1999.1743. Eur Heart J. 2000. PMID: 10666351 Clinical Trial.
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.
Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML. Boersma E, et al. Among authors: topol ej. Circulation. 2000 Jun 6;101(22):2557-67. doi: 10.1161/01.cir.101.22.2557. Circulation. 2000. PMID: 10840005 Clinical Trial.
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
Ronner E, Boersma E, Akkerhuis KM, Harrington RA, Lincoff AM, Deckers JW, Karsch K, Kleiman NS, Vahanian A, Topol EJ, Califf RM, Simoons ML. Ronner E, et al. Among authors: topol ej. Eur Heart J. 2002 Feb;23(3):239-46. doi: 10.1053/euhj.2001.2736. Eur Heart J. 2002. PMID: 11792139 Clinical Trial.
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes.
Roe MT, Mahaffey KW, Kilaru R, Alexander JH, Akkerhuis KM, Simoons ML, Harrington RA, Tardiff BE, Granger CB, Ohman EM, Moliterno DJ, Lincoff AM, Armstrong PW, Van de Werf F, Califf RM, Topol EJ. Roe MT, et al. Among authors: topol ej. Eur Heart J. 2004 Feb;25(4):313-21. doi: 10.1016/j.ehj.2003.12.009. Eur Heart J. 2004. PMID: 14984920 Free article. Clinical Trial.
1,303 results